Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tutram
- Development stage
- Unknown
- Lead developer
- Nippon Zoki Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tutram (also known as Twotram or NZ-687) is an oral, twice-daily bilayer tablet formulation of tramadol hydrochloride developed by Nippon Zoki Pharmaceutical. It consists of a 35% immediate-release layer and a 65% sustained-release layer, designed to provide rapid onset of analgesia followed by stable, long-lasting pain relief. Tramadol acts as a weak mu-opioid receptor agonist and also inhibits the reuptake of norepinephrine and serotonin. Tutram is approved in Japan for the management of cancer pain and chronic pain that is difficult to treat with non-opioid analgesics.
- Brand names
- TutramTwotramツートラム
- Other names
- sustained-release tramadol bilayer tabletstramadol hydrochloride bilayer tablets
02
Targets
MOR (Mu opioid receptor)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on Tutram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tutram.